AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$EVH

Evolent Health: Q3 Earnings Snapshot

Evolent Health (EVH) reported a Q3 loss of $23.6M, or 21 cents per share, with adjusted earnings of 6 cents per share, meeting expectations. Revenue was $725.4M, below the $734.3M forecast. The company expects full-year revenue between $2.6B and $2.7B.

Original reporting
finance.yahoo.com
Published Nov 5, 2026, 12:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 12:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Evolent Health: Q3 Earnings Snapshot — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$EVHBearishMed
01

Why it matters

The earnings miss may trigger short‑term selling, but the full‑year revenue guidance leaves room for recovery.

02

Market read

First‑time earnings disclosure with a revenue miss; relevant for traders tracking health‑tech mid‑caps.

03

What to watch

Potential upside from upcoming contract wins or cost‑reduction initiatives not disclosed in the release.

Relevance 7/10Novelty 7/10Timing: after-market release

Background

Evolent Health is a provider of health‑care software and consulting services, listed on NASDAQ under EVH.

Company-level read

Ticker impact

$EVHBearishHigh confidence
Context

Evolent Health reported Q3 loss of $23.6M and revenue miss ($725.4M vs $734.3M estimate).

Expected impact

downside pressure as market prices in the revenue shortfall and loss.

Evidence & confidence

Both earnings per share and revenue fell short of expectations, a clear negative catalyst.

Market effects

Sector

Health‑care software sector may see modest pullback as earnings miss highlights demand pressures.

Regional

U.S. market participants may adjust exposure to mid‑cap health‑tech stocks.

Global

Limited; impact confined to U.S. health‑tech equities.

Counterpoint

What could challenge this read

If the loss is viewed as a one‑time adjustment, the stock could rebound on the guidance range of $2.6‑$2.7B.

Key entities

  • company
    Evolent Health Inc.

    Health‑care software and consulting services provider.

Read at source← All news

StoryEvolent Health posts Q3 2026 loss, lifts full‑year Adjusted EBITDA guidance

Also covered by

5 outlets

Related articles

$EVHMedAI 8/10

EVH Q3 2026 deep dive: ongoing AI investment and customer expansion shape outlook

EVH reported Q3 2026 revenue of $725.4M (51.3% YoY growth, in line with estimates) and adjusted EPS of $0.06 (in line). Adjusted EBITDA was $34.26M, beating estimates by 3.1%. The company reconfirmed full-year revenue guidance of $2.65B and raised EBITDA guidance to $132.5M. Sales volumes fell 4.2% YoY, while operating margin declined to -0.9%. EVH expanded its AI platform, Oncology care, and National payer scale, citing cost savings and margin expansion potential.

finance.yahoo.com
$EVHMed

Evolent Health, Inc. Q3 2026 Earnings Call Summary

Evolent Health reported 11% sequential revenue growth driven by Highmark Performance Suite and contractual adjustments. MER improved to 93%. Management prioritizes margin expansion and cash generation, with oncology expected to represent over 70% of revenue by 2027. AI platform scales, processing 1M cases annually. Management reiterated 2027 Adjusted EBITDA confidence of $150M+ and plans $50M debt reduction by 2026 year-end.

finance.yahoo.com
$EVHMedAI 8/10

Evolent Health (EVH) Q3 2026 Earnings Call Transcript

Evolent Health (EVH) reiterated its full-year revenue guidance of $2.6B-$2.7B and raised Adjusted EBITDA guidance to $130M-$135M. The company reported customer contract renewals and expansions, including a 4-year renewal with its largest Surgical Management customer and expansions in oncology and specialty services.

finance.yahoo.com
$EVHMed

Evolent Announces Third Quarter 2026 Results

Evolent Health, Inc. (EVH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Evolent Announces Third Quarter 2026 Results WASHINGTON (November 5, 2026) – Evolent Health, Inc. (NYSE: EVH) (“Evolent” or the “Company”), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make heal

SEC EDGAR 8-K